134 related articles for article (PubMed ID: 7906263)
1. 5'-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression.
van der Heyden S; Gheuens E; van de Vrie W; Van Bockstaele D; Van Oosterom A; Eggermont A; De Bruijn EA
Jpn J Cancer Res; 1994 Jan; 85(1):13-6. PubMed ID: 7906263
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.
Armstrong RD; Diasio RB
Cancer Res; 1980 Sep; 40(9):3333-8. PubMed ID: 6253060
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
4. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
5. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA
Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.
Spoelstra EC; Dekker H; Schuurhuis GJ; Broxterman HJ; Lankelma J
Biochem Pharmacol; 1991 Feb; 41(3):349-59. PubMed ID: 1671638
[TBL] [Abstract][Full Text] [Related]
8. Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.
Armstrong RD; Diasio RB
Cancer Res; 1981 Dec; 41(12 Pt 1):4891-4. PubMed ID: 6171343
[TBL] [Abstract][Full Text] [Related]
9. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
Gupta S; Patel K; Singh H; Gollapudi S
Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
[TBL] [Abstract][Full Text] [Related]
10. Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles.
Guiral M; Viratelle O; Westerhoff HV; Lankelma J
FEBS Lett; 1994 Jun; 346(2-3):141-5. PubMed ID: 7912204
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on the antitumor and immunosuppressive effects of the new fluorouracil derivative N4-trimethoxybenzoyl-5'-deoxy-5-fluorocytidine and its parent drug 5'-deoxy-5-fluorouridine.
Miwa M; Ishikawa T; Eda H; Ryu M; Fujimoto K; Ninomiya Y; Umeda I; Yokose K; Ishitsuka H
Chem Pharm Bull (Tokyo); 1990 Apr; 38(4):998-1003. PubMed ID: 2143107
[TBL] [Abstract][Full Text] [Related]
12. A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin.
Cheng J; Wang J; Chen B; Xia G; Cai X; Liu R; Ren Y; Bao W; Wang X
Int J Nanomedicine; 2011; 6():2123-31. PubMed ID: 22114476
[TBL] [Abstract][Full Text] [Related]
13. 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
Armstrong RD; Cadman E
Cancer Res; 1983 Jun; 43(6):2525-8. PubMed ID: 6221792
[TBL] [Abstract][Full Text] [Related]
14. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells.
Laredo J; Huynh A; Muller C; Jaffrézou JP; Bailly JD; Cassar G; Laurent G; Demur C
Blood; 1994 Jul; 84(1):229-37. PubMed ID: 7912555
[TBL] [Abstract][Full Text] [Related]
15. Increased cytotoxicity of 5'-deoxy-5-fluorouridine by prolonged culture with folinic acid.
Matsuoka H; Furusawa M; Tomoda H; Seo Y; Sugimachi K
Anticancer Res; 1993; 13(6A):2201-6. PubMed ID: 8297134
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cytotoxic activity of 5'-deoxy-5-fluorouridine.
Armstrong RD; Connolly KM; Kaplan AM; Cadman E
Cancer Chemother Pharmacol; 1983; 11(2):102-5. PubMed ID: 6226452
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
Armstrong RD; Gesmonde J; Wu T; Cadman E
Cancer Treat Rep; 1983 Jun; 67(6):541-5. PubMed ID: 6222789
[TBL] [Abstract][Full Text] [Related]
18. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin.
Loetchutinat C; Heywang C; Priebe W; Garnier-Suillerot A
Biochem Pharmacol; 2001 Sep; 62(5):561-7. PubMed ID: 11585053
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and interaction with uridine phosphorylase of 5'-deoxy-4',5-difluorouridine, a new prodrug of 5-fluorouracil.
Ajmera S; Bapat AR; Stephanian E; Danenberg PV
J Med Chem; 1988 Jun; 31(6):1094-8. PubMed ID: 2967375
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
